Literature DB >> 23261448

Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.

Cristian A Lasagna-Reeves1, Audra L Clos, Diana Castillo-Carranza, Urmi Sengupta, Marcos Guerrero-Muñoz, Brent Kelly, Richard Wagner, Rakez Kayed.   

Abstract

The tumor suppressor p53 plays an important role in genome integrity. It is frequently mutated in all types of human cancers, making p53 a key factor in cancer progression. Two phenotypic consequences of these alterations are dominant; a loss of function and a gain of function of p53, which, in several cases, accumulates in intracellular aggregates. Although the nature of such aggregates is still unclear, recent evidence indicates that p53 can undergo conformational transitions leading to amyloid formation. Amyloid diseases, such as, Alzheimer's disease, are characterized by the accumulation of insoluble aggregates displaying the fibrillar conformation. We decided to investigate the propensity of wild type p53 to aggregate and its consequent assembly into different amyloid species, such as oligomers and fibrils; and to determine if these changes in conformation lead to a loss of function of p53. Furthermore, we analyzed cases of Basal Cell Carcinoma (BCC), for the presence of p53 amyloids. Here, we show that p53 forms amyloid oligomers and fibrils, which coincide with p53 inability of binding to DNA consensus sequences. Both p53 amyloid oligomers and fibrils were detected in BCC cancer samples. Additionally, we demonstrate that p53 oligomers are the most cytotoxic to human cell cultures. Our study reveals p53 amyloid formation and demonstrates its dual role in the pathogenesis of cancer by producing a loss of protein function and a gain of toxic function, extensively described in several amyloidogenic diseases. Our results suggest that under certain circumstances, cancer could be considered a protein-conformation disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261448     DOI: 10.1016/j.bbrc.2012.11.130

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  p53 protein aggregation promotes platinum resistance in ovarian cancer.

Authors:  Y Yang-Hartwich; M G Soteras; Z P Lin; J Holmberg; N Sumi; V Craveiro; M Liang; E Romanoff; J Bingham; F Garofalo; A Alvero; G Mor
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

2.  Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.

Authors:  Gu Xiao; George K Annor; Kimberly Fung; Outi Keinänen; Brian M Zeglis; Jill Bargonetti
Journal:  Mol Pharm       Date:  2020-12-08       Impact factor: 4.939

3.  Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.

Authors:  Naoyuki Iwahashi; Midori Ikezaki; Taro Nishikawa; Norihiro Namba; Takashi Ohgita; Hiroyuki Saito; Yoshito Ihara; Toshinori Shimanouchi; Kazuhiko Ino; Kenji Uchimura; Kazuchika Nishitsuji
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-14       Impact factor: 11.205

4.  p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.

Authors:  Saikat Ghosh; Shimul Salot; Shinjinee Sengupta; Ambuja Navalkar; Dhiman Ghosh; Reeba Jacob; Subhadeep Das; Rakesh Kumar; Narendra Nath Jha; Shruti Sahay; Surabhi Mehra; Ganesh M Mohite; Santanu K Ghosh; Mamata Kombrabail; Guruswamy Krishnamoorthy; Pradip Chaudhari; Samir K Maji
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

Review 5.  Potential of rescue and reactivation of tumor suppressor p53 for cancer therapy.

Authors:  Emi Hibino; Hidekazu Hiroaki
Journal:  Biophys Rev       Date:  2022-01-11

6.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

7.  A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.

Authors:  Alice Soragni; Deanna M Janzen; Lisa M Johnson; Anne G Lindgren; Anh Thai-Quynh Nguyen; Ekaterina Tiourin; Angela B Soriaga; Jing Lu; Lin Jiang; Kym F Faull; Matteo Pellegrini; Sanaz Memarzadeh; David S Eisenberg
Journal:  Cancer Cell       Date:  2015-12-31       Impact factor: 31.743

Review 8.  Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?

Authors:  Danielly C F Costa; Guilherme A P de Oliveira; Elio A Cino; Iaci N Soares; Luciana P Rangel; Jerson L Silva
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-10-03       Impact factor: 10.005

Review 9.  The "Jekyll and Hyde" Actions of Nucleic Acids on the Prion-like Aggregation of Proteins.

Authors:  Jerson L Silva; Yraima Cordeiro
Journal:  J Biol Chem       Date:  2016-06-10       Impact factor: 5.157

Review 10.  Mutations, protein homeostasis, and epigenetic control of genome integrity.

Authors:  Jinglin Lucy Xie; Daniel F Jarosz
Journal:  DNA Repair (Amst)       Date:  2018-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.